The phase III OlympiAD trial demonstrated that maintenance therapy with Olaparib significantly increased PFS in patients with metastatic HER2-negative BRCA-mutated breast cancer, in comparison to standard chemotherapy (Robson et al., 2017, 2019). This evidence concerns the gene ERBB2 and breast carcinoma.